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Summary: Serum concentrations of total cholesterol and lipoprotein cholesterol, of apolipoproteins AI and
AII and of apolipoprotein AI in lipoprotein particles (Lp AI and Lp A) were determined in 43 patients
with multiple myeloma.
There were striking alterations in the plasina levels of these analytes relative to normal subjects.
We observed a decrease of cholesterol levels in LDL, HDL and HDL3 fractions, and of apolipoproteins AI
and AII compared with normal subjects. The HDL2 cholesterol was increased.
The decrease of apolipoprotein A II was more prominent than apolipoprotein AI.
The decrease of apolipoprotein A I concerns only the A I (Lp A), while the AI (Lp AI) was increased.
Most of these modifieations were correlated with the monoclonal Ig levels.
Introduction
 t . t . . , „ · * _ , iwhich were inversely correlated with the monoclonal
Most patients sufferiüg from multiple myelomatosis immunoglobulin level (4). These two parameters ap-
show disturbances in serum cholesterol and lipopro-r pear to play central roles in corporeal cholesterol
teins (l —3). Fiessinger et al. (3) described a decrease metabolism. The presence of several HDL classes has
in -üpoproteins and less freqüently ßJipoproteins been confinned in many studies. In the studies of
with hypocholesterolaemia in myeloma patient$ and Gofman et al. (5) HDL was separated by ultracentri-
suggested that these decreases were associated with fugation based on density flotation into three subpo-
progressive disease. We have observed thät the same pulations: HDL!, HDL2 and HDL3. Without doubt,
disease state is accompanied by decreases of HDL HDL2 and HDL3 are the major HDL populations
cholesterol and apolipoprotein AI concentrations present in the plasma. As previously described, these
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subfractions could play distinct metabolic roles in
pathological events (6, 7) or cellular cholesterol
metabolism in vitro (8, 9). Apolipoprotein AI exists
in at least two different types of lipoprotein particles
in human plasma (10, 11). More than 50% of total
apolipoprotein A I is associated with apolipoprotein
AII (Lp A particles) while the rest exists in lipopro-
teins that contain no apolipoprotein All (Lp AI
particles). These two populations of particles appar-
ently may represent trwo metabolically distinct pools
of apolipoprotein A I-containing lipoproteins (11).
The basis of the lower HDL cholesterol concentra-
tions present in subjects with myelomatosis has not
been previously elucidated. In view of the possibility
of a distinct metabolic role for HDL-containing parti-
cles, it is of interest to determine which particle is
involved in HDL pertubations in myeloma disease.
This study was undertaken to determine the level of
cholesterol associated with LDL, HDL, HDL2 and
HDL3, the circulating mass of apolipoprotein AI
and A II,\ and the AI concentrations of lipoprotein
particles containing AI associated or unassociated
with AII (AI (Lp A) and AI (Lp A I)) in patients
suffering from myeloma. These studies increase our
understanding of the pathological events which occur
in cholesterol metabolism in myeloma.
Materials and Methods
Clinical populations
Studies were performed on 43 patients with multiple myeloma
(28 females and 15 males). The diagnosis was based both on
bone marrow histology and on the presence of monoclonal Ig
or light chain gammopathy. The monoclonal gammopathies
were IgG Kappa in 23 patients, IgG Lambda in 10 patients,
IgA Lambda in 3 patients, IgA Kappa in 6 patients and Kappa
light chains in one patient. The ages of the patients ranged
between 40 and 60, except for 3 patients aged 75, 78, and 80
(10 patients between 40 and 50 years; 30 patients between 50
and 60 years).
On the basis of clinical examination and Standard biological
Parameters of hepatic function (serum aspartate aminotransfer-
ase, alanine aminotransferase, lactate dehydrogenase, alkaline
phosphatase and bilirubin), they were considered äs having
normal liver function at the time of the blood sampling.
Since initial analysis indicated no differences between male and
female patients, the data for the two groups were combined
for the statistical analysis.
Sixty eight healthy nonnolipidaemic subjects were used äs con-
trols for triacylglycerols and cholesterol, and thirty äs controls
for plasma apolipoprotein AI of lipoprotein particles (A I (Lp
A I) and A I (Lp A)) and for plasma apolipoproteins A I and
A II. The age distribution of these two populations was in the
same ränge äs the myeloma patients.
Blood samples were obtained by venipuncture from subjects
who had fasted overnight. The blood was collected in 10 ml
vacutainer tubes containing 0.5 ml of 5 mmol/1 EDTA, and
centrifuged for 15 min at 2500 min-1 at 4 °C to separate cells
from plasma. Plasma samples were kept frozen for more than
one month, at — 20 °C until analysis. In these conditions, no
significant lipid or apolipoprotein modifications were observed.
Reagents
Manganese chloride and heparin sodium salt were purchased
from Sigma Chemical Company; and dextran sulphate (Afr =
15000) was obtained from Sochifeo -3-5, rue Carnot, 92100
Boulogne-sur-Seine, France). All other reagents were of analyti-
cal grade.
Analytical methods
Plasma cholesterol and triacyglycerol (12, 13) concentrations
were determined by enzymatic methods. LDL cholesterol was
determined by a precipitation method (BioMerieux, Marcy-
l'Etoile 69260 Charbonnieres les Bains, France) äs was the
cholesterol associated with HDL, HDL2 and HDL3 (12).
Determination öf apolipoproteins A l and A II and
of A I in lipoprotein particles (Lp A and Lp A I)
Apolipoprotein AI and A II were determined by
tive enzyme-linked immunosorbent assay (14, 15)
The quantitative determination of A I (Lp A) and AI (Lp AI)
was performed using an automated enzyme-linked differential
antibody immunosorbent technique, on microtitre plates. The
procedure is described in detail elsewhere (16).
Briefly, the method consisted of two assays:
a) Measurement of total apolipoprotein AI by non^cpmpetitive
enzyme-linked immunoassay (14). Here, antibodies to apolipo-
protein AI were coated on microtitre plates. After incubation
with undelipidated plasma at various dilutioris, the total
amount of apolipoprotein AI retained by these first antibodies
was evaluated using peroxidase-labeled antibodies to apolipo-
protein AI (A I (Lp A) + A I (Lp AI)).
b) For the measurement of AI (Lp A), the plate wells were
coated with antibodies to apolipoprotein A II. After incubation
with samples, only A I (Lp A) Jipoproteins were retained while
A I (Lp AI) lipoproteins were removed in the washing process.
The amount of apolipoproteins AI associated with AII was
then evaluated by using again peroxidase labeled antibodies to
apolipoprotein AI.
Apolipoprotein AI unassociated with AII was evaluated by
substracting the concentratioii of AI (Lp A) from total AI.
The assay of apolipoprotein A I associated with AII was linear
over the ränge of 0.005 to 0.05 g/l. Within- and between^assäy
CVs were 5.6 and 9.8% respectively (16). LpA isolated from
plasma from a normolipidaemic fasting subject was used äs
Standard.
Statistical studies
A preliminary statistical study based on an F lest indicates ä
discrepancy between the variaiices of controls and myeloma
populations. Comparisom of means was carried o\it by the
Mann-Withney U-test. Spearmarfs test was used to identify
significant (p < 0.05) relationships between parameters.
Results
Table l shows the results obtained for total chol-
esterol, HDL and IJDL subfractions arid LDL chol-
esterol. Whereas total cholesterol was not modified,
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Tab. 1. Comparative studies of total cholesterol, lipoprotein choiesterol and triacyglycerol concentrations (mean ± SD) between
myeloma patients and the control group.
N S : not significant
* : p < 0.05
** : p < 0.01
*** : p < 0.001
**** : p < 0.0001
Control group
N = 68
Myeloma patients
N = 43
Total
cholesterol
mmol/1
5.65 ± 1.00
5.38 ± 1.17
NS
HDL
cholesterol
mmol/1
1.44 ± 0.36
1.07 ± 0.50
***
HDLz
cholesterol
mmol/1
0.21 ± 0.19
0.35 ± 0.26
*
HDL3
cholesterol
mmol/1
1.22 ± 0.27
0.72 ± 0.39
****
LDL
cholesterol
mmol/1
3.75 ± 0.89
2.63 ±1.11
****
Triacyl
glycerols
mmol/1
1.05 ± 0.4
1.45 ± 0.6
**
Tab. 2. Comparative studies of apolipoproteins A I and AII, AI (Lp A I) and A I (Lp A) concentrations (mean ± SD) between
myeloma patients and the control group.
* p < 0.05
** p < 0.001
*** p < 0.0001
Control group
N = 30
Myeloma patients
N = 43
Apolipoprotein A I
g/l
1.31 ±0.25
1.05 ± 0.37
**
Apolipoprotein A II
g/l
0.44 ± 0.08
0.21 ± 0.07
***
A I (Lp A I)
g/l
0.43 ± 0.28
0.55 ± 0.20
A I
g/l
0.83
0.50
***
(Lp A)
±0.20
± 0.21
the HDL cholesterol levels were significantly de-
creased (p < 0.001; tab. 1) in myeloma patients. The
mean and SD of HDL chölesterol levels were l .07
± 0.50 mmol/1 compared with 1.44 ± 0.36 mmol/1
in healthy subjects. This decrease affected particularly
the HDL3 subfraction (p < 0.001); the HDL2 cho-
lesterol was increased in myeloma (p < 0.001). This
finding and the lower LDL cholesterol levels
(p < 0.0001); 70% of cases) suggest that VLDL cho-
lesterol must be elevated in this disease. Indeed ap-
proximate VLDL cholesterol concentrations (ob-
tained by total cholesterol minus HDL cholesterol
plus LDL cholesterol) were higher in myeloma
patients (1.64 + 0.78 mmol/1 compared with 1.23
± 0.49 mmol/1 in control group, p < 0.01):
Consistent with this proposal is the qbservation that
the myeloma patients have significantly higher
plasma triacyglycerol levels (1.45 ± 0.6 mmol/1;
p < 0.01) than controls (1.05 ± 0.4 mmol/1).
The plasma concentrations of both apolipoproteins
AI and AII, and AI associated with AII (A I (Lp
A) were significantly decreased in myeloma
(p < 0.01; tab; 2). The apolipoprotein All levels
(86% of cases, p < 0.0001) were more diminished
than apolipoprotein AI (44% of cases, p < 0.001;
tab. 2). This was consistent with the observation that,
unlike AI (Lp A), the AI (Lp AI) levels were actually
higher in myelomatosis (p < 0.05; tab. 2).
Plasma AI (Lp AI) and AI (Lp A) concentrations
correlated positively with the cholesterol content of
HDL, HDL2 and HDL3 (tab. 3). The proportion of
these two types of particles varied with the ratio of
HDL2 and HDL3 in the plasma (11). In the same
manner, the plasma AI (Lp AI) concentrations were
Tab. 3. Degree of significant linear association (r) among LDL
cholesterol, HDL cholesterol, AI (Lp AI), and AI
(Lp A) with the cholesterol of lipoprotein fractions in
myeloma patients.
* : p < 0.001
**': p < 0.0001
Parameters r p
HDL-Chol vs HDLrChol
HDL-Chol vs HDL3-Chol
A I (Lp A I) vs HDL-Chol
A I (Lp A I) vs HDLrChol
A I (Lp A I) vs HDL3-Chol
A I (Lp A) vs HDL-Chol
A I (Lp A) vs HDLrChol
A I (Lp A) vs HDL3-Chol
0.678
0.839
0.718
0.548
0.550
0.877
0.502
0.851
**
**
**
*
*
**
*
**
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positively correlated with A I (Lp A) concentrations
(r = 0.681; p < 0.001), while the HDL2 cholesterol
was not correlated with the HDL3 cholesterol. No
relationship is noticed between LDL cholesterol and
the other parameters.
Table 4 shows an inverse relationship between the
monoclonal Ig levels and the plasma apolipoproteins
AI and AII, and the AI (Lp AI), AI (Lp A), HDL
and HDL3 cholesterol concentrations. The increase
in cholesterol HDL2 concentration was monoclonal
Ig-independent. However, the small number of alpha
chain myeloma cases (n = 9) made it impossible to
detennine whether there was a correlation between
Ig isotype and the disturbed parameters.
Tab. 4. Degree of linear association (r) among monoclonal Ig
with apolipoproteins AI and AII, AI (Lp AI), AI
(Lp A) and with the cholesterol of lipoprotein fractions
in myeloma patients.
* p < 0.05
** p < 0.01
*** p < 0.001
• \
Ig vs
Apolipoprotein A I
Apolipoprotein A II
A I (Lp A I)
A I (Lp A)
LDL-cholesterol
HDL-cholesterol
HDL2-cholesterol
HDL3-cholesterol
r
- 0.512
- 0.496
- 0.342
- 0.528
- 0.320
- 0.559
- 0.233
- 0.583
P
***
**
*
***
*
***
NS
***
Discussion
Our data showed significant decreases' of LDL, HDL
and HDL3 cholesterol, of apolipoproteins A I and
AII and of A I (Lp A) in the plasma of patients with
myelomatosis. In contrast with previous reports (l,
3), total plasma cholesterol was not «ignificantly af-
fected by the disease.
Increased elimination rates of ß-lipoprotein and a-
lipoprotein by the reticuloendothelial System follow-
ing complex formation with the pathological globulin
in the plasma might be the basis of the reduced
plasma LDL- and HDL-cholesterol concentrations
in our patients, äs suggested by Fiessinger et al. (3).
This hypothesis has never been confirmed in vivo and
indeed identical lipid perturbations occur in the other
haematological diseases such äs leukaemiä (17), a
disease that does not show abnormal immunoglobu-
lin synthesis. Bases & ATrafcöj^demonstrated increased
phagocytic activity of the reticuloendothelial System
in patients with chronic myeloproliferative disorders
and hypocholesterolaemia (18) without complex' for-
mation of lipoprotein with pathological globulin in
the plasma. In the same disease, Ginsberg et al. (19)»
observed reduced LDL cholesterol concentrations
and suggested that these were associated with in-
creased non receptor-mediated catabolism of LDL
apolipoprotein B. If the reduced LDL-cholesterol
in myeloma was due to increased activity of the
reticuloendothelial System, why is an identical process
not involved in HDL metabpjism? Indeed, we have
observed an increase of cholesterol in HDL2 without
association with the tumofal mass expressed by the
pathological immunoglobulin levels. These observa-
tions suggest that a more specific mechanisin is likely
for the reduced LDL concentrations of patients with
myeloma disease, bäsed öü increased LDL receptor-
mediated uptake and degradation of LDL. Cells that
have undergone malignant transformation are known
to have altered cholesterol metabolism (20, 21), and
low LDL cholesterol levels in patients with acute
leukaemia are the result of increased receptor-medi-
ated LDL uptake and degradation by leukaemic cells
.äs suggested by Vitols et al. (17). An increased load
*of myeloma plasmocyte cells could conceivably alter
:
 plasma cholesterol levels^ and the marked decreases
of cholesterol concentrations in HDL, particularly
into HDL3, were consistent with an LDL receptor-
dependent process. Oram (9) demonstrated in cul-
tured human fibroblasts and human arterial smooth
muscle cells, that exposure of cells to HDL3 and
VHDL removes cholesterol from cells and also results
in elevated LDL receptor activity and an enhanced
rate of LDL degradation by the cells.
We can suppöse that in myeloma patients, the de-
creased cholesterol HDL3 levels were due to HDL3-
cellular interaction. This interaction of HDL3 with
tumour plasmocyte cells results in a rapid increase in
LDL receptor activity in parallel to an increase in
the rate of cholesterol synthesis and a decrease in
the rate of cholesterol esterification, äs suggested by
several author s (22, 8) for cultured human fibroblasts.
The correlations observed in our patients between
cholesterol levels or LDL and HDL3 with the disease
state Supports this hypothesis. It has been postulated
that the efflux of cholesterol from the cell is mediated
by the bindiüg of HDL to high-affinity sites (22, 23).
Repent work by Fielding et al. (24) has indicated that
sterol efflux from fibroblasts is dependent upon a
minor lipoprotein fraction containing apolipoprotein
A unassociäted with other major lipoproteins. The
increased mass of circulating A I (Lp A I) observed
in our patients in relation to the disease state Support
this hypothesis. The increased HpL2-chQlesterpl in
our patients wöüld be explained by the availability
öf lipid transport proteins that may "drive" the chol-
esterol transport process (28). The decrease of total
plasma apolipoproftein A (activator of lecithin-cho-
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lesterol acyltransferase) might induce a decrease of
lecithin cholesterol acyltransferase and an increase of
apolipoprotein E-rich HDL (25). Fielding et al. (26)
have demonstrated that unassociated apolipoprotein
E promotes sterol efflux. At that time, however, data
on apolipoprotein E levels in myeloma were not avail-
able.
Elsewhere we cannot rule out the hypothesis that
myeloma HDL have altered structure with an accom-
panying increase in their catäbolism. These structural
modifications could result from Substitution of apoli-
poproteins AI and AII by another protein resulting
from the disease. This phenomenon of one apolipo-
protein displacing another has been shown by several
authors (27, 28, 29).
Preliminary results in our laboratory have shown
the presence of serum amyloid A protein (SAA) in
myeloma HDL. Parks et al. (30) have described, in
a non-human primate, a displacement of AI, AII or
C-apolipoproteins from HDL after induction with
serum amyloid A protein.
We think that the presence of serum amyloid A pro-
tein could modulate the HDL surface and conse-
quently facilitate the binding of HDL via specific
sites to tumour cells. The decrease of apolipoproteins
AI and AII, particularly of AI (Lp A) with relation
to disease state could conceivably support this hy-
pothesis. At least, these two apolipoproteins (A I and
AII) are localized at the periphery of the lipoprotein
particle (31).
Studies are in progress in our laboratory to delineate
the mechanism involved in the production of these
perturbations in patients suffering from myeloma.
Our results suggest that determination of apolipopro-
tein AI, associated or unassociated with A II, provide
Information that may be of value in assessing myelo-
ma disease activity.
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